Glaxo analysis of Lamictal found a trend for suicidal thoughts and behavior that was similar to the FDA analysis, company spokeswoman Holly Russell said. 葛兰素史克公司发言人HollyRussell宣布,一项关于Lamictal的分析结果发现存在自杀想法和行为的趋势,这和FDA的分析相类似。
In the study, Lamictal was given to patients whose seizures were not well controlled, even while taking one or two other anti-seizure medications. 在这项研究中,只有在服用了一种甚至两种药物而癫痫症状仍没有很好控制的病人才服用了拉莫三嗪。
These new disintegrating tablets were approved on the basis of their demonstrated bioequivalence to Lamictal tablets and were developed in collaboration with Eurand NV. 在验证了与拉莫三嗪普通片剂的生物等效性后,拉莫三嗪口腔崩解片被批准,由葛兰素史克与尤兰德EurandNV合作开发。
Lamictal is also approved as maintenance therapy for adults with bipolar I disorder. 拉莫三嗪同时也被批准为成人的双极I综合症紊乱的维持治疗。